Plus Ruis

I. Company Profile: Plus Ruis (Shanghai) Pharmaceutical Technology Development Co., Ltd. focuses on SMO business. Founded in 2013, it is one of the earliest SMO companies in China. In May 2022, it was officially listed on the ChiNext of the Shenzhen Stock Exchange, becoming an A-share listed SMO company in China, with stock code: Plus Ruis 301257.SZ. Plus Ruis is a big-data-driven clinical research service provider that adheres to a 'patient-centered' approach. By deconstructing clinical trials and actual hospital scenarios, the company has created a full-process project management system for clinical trials. Deeply engaged in the SMO (Site Management Organization) business, and based on experience from over 4,600 projects, it provides clients with data-driven execution plans in a relatively short time, helping clients improve trial execution efficiency and data quality, and accelerating the availability of new drugs to patients. As of the end of March 2026, the company had 4,526 employees, including over 4,300 professional business personnel. The company has served more than 970 clinical trial institutions in total, covering over 1,300 clinical trial institutions, with services spanning more than 200 cities nationwide, meeting the needs of most client projects. As of the end of December 2025, the company had facilitated the listing of over 230 products domestically and internationally. As of the end of March 2026, the company had 2,713 ongoing projects and had participated in more than 4,600 SMO projects cumulatively. The company's services cover many fields and have strong competitive advantages in several disease-specific areas, including hematological tumors, thoracic tumors, gastrointestinal tumors, cardiovascular diseases, urological tumors, endocrine diseases, infectious diseases, and rheumatology and immunology. Plus Ruis adheres to long-termism, is always committed to sustainable development, and integrates ESG concepts into all aspects of daily operations, continuously paying attention to and actively responding to the needs of various stakeholders, including customers, employees, shareholders and investors, suppliers, partners, communities, and the public. With excellent service capabilities and industry contributions, the company has received awards such as 'Zhangjiang Star,' 'High-tech Enterprise,' 'Huangpu District Private Enterprise Headquarters,' and 'Huangpu District Enterprise Technology Center.' In the first half of 2026, the company released its 2025 ESG report, systematically disclosing its practices and achievements in sustainable development management, corporate governance, social contribution, and environmental dimensions. The company's excellent ESG performance has been recognized by professional institutions, with a Wind ESG rating of A, and it has received honors such as '2025 ESG Market Model,' '2025 ESG New Benchmark Enterprise Award,' and '2025 Listed Company Sustainable Development Excellent Practice Case.' The company always attaches importance to the development and application of digital and intelligent technologies, treating them as important development strategies. On January 7, 2026, the 'Ruixing Clinical Trial Text Generation Algorithm,' independently developed by Plus Ruis, successfully passed the national filing for deep synthesis service algorithms. Through independent development and other forms, the company has built an efficient and collaborative clinical trial execution management platform, integrating new technologies such as artificial intelligence, and incorporating advanced quality management systems into the platform to achieve data visualization and intelligent management, improve execution efficiency, and help the company provide high-quality clinical trial outsourcing services to more clients. In the process of communication, coordination, and project implementation management with sponsors, clinical trial institutions, and researchers, the company can respond quickly and provide timely feedback, ensuring efficient advancement of clinical research, accelerating the clinical research process, and shortening research cycles. For more information about Plus Ruis: *